Kornimate/medical-research-clean huggingface dataset:
nasolacrimal duct obstruction

Conditions: Eye Diseases; Lacrimal Duct Obstruction

Summary: 1.1 background obstructions of the lacrimal drainage system can be differentiated based on anatomical location or severity. but also, differentiating between congenital and acquired nasolacrimal duct obstruction (nldo) is possible. the incidence of congenital nldo (cnlod) has been shown to be approximately 20%. most of the cases undergo spontaneous remission, as the ductus nasolacrimalis may open spontaneously. about 2-12% display a symptomatic course. 2. s: 290; 3; 4, 5 acquired nldo may occur during childhood and adulthood. the incidence of symptomatic acquired nldo is around 30 cases per 100.000 people in an us-based cohort study. s: 293; 30 two major anatomical closure sites have been described, which are on the one hand located at the between the punctum and canaliculus, and on the other hand located after the lacrimal sac. 1. s. ; 2. s: 293 1.2 aim of this study the aim of this study is to assess the success rates for different types of primary tear duct surgery, performed from 2013 - 2017 at the department of ophthalmology and optometry, medical university of vienna. treatment success was defined as the absence of clinical signs of lacrimal drainage system obstruction (epiphora, increased tear leak, mucous discharge) and without the need for re-intervention. it is further investigated whether the type of operation performed or whether the silicone tube used influence success rates. 1.3 methods a retrospective chart analysis of all patients - independent of the underlying pathology - undergoing surgery of the lacrimal drainage system between 1st of january 2013 and 31st december 2017. success rates and patient profiles will be analyzed not only for all patients, but also for subgroups based on the underlying pathology and operation performed.


Eligibility criteria:
inclusion criteria * all charts of patients treated during the above-indicated period of time will be considered for this analysis. exclusion criteria * incomplete medical records are considered an exclusion criterion.
how does mindfulness meditation buffer the negative effects of pain and suffering in the covid-19 world? (pain sample)

Conditions: Pain, Intractable; Pain, Chronic

Summary: both mindfulness meditation and expectancy effects are known to reduce pain intensity, pain unpleasantness and pain catastrophizing, but it is unknown whether and how expectancy effects contribute to the overall effect of mindfulness meditation on these outcomes, especially during significant global events such as the coronavirus pandemic. this study includes four interrelated aims that will probe these effects and interactions.

as many as 1 in 4 australians experience chronic pain. further, it is yet unknown the effects of the coronavirus (covid-19) pandemic on australians with or at risk of chronic pain. there is a critical need for the development and evaluation of fast-acting non-pharmaceutical treatments that have the capacity to target the multidimensional nature of chronic pain. this study will investigate how mindfulness meditation and common expectancy effects interact and will further characterise the mechanisms underlying these effects. results will ultimately lead to targeted interventions that more effectively engage cognitive mechanisms associated with pain attenuation.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * recurrent pain (two or more days in the last month) * chronic pain (pain most days in the last three months) * able to read and understand english exclusion criteria: * not experiencing recurrent or chronic pain * incomplete or invalid data (response time \< 32 minutes, failing attention checks) * completing the 20-minute training module in \ 90 minutes
the mind-bc study: mind diet for breast cancer cognition

Conditions: Breast Cancer

Summary: this fully, powered efficacy rct, the mind diet for breast cancer cognition (mind-bc), will evaluate the mind diet in a rigorous, highly controlled academic cancer center. we will recruit breast cancer survivors reporting crci with a mind diet score \< 8, based on a previously devised 14-item diet questionnaire designed to detect inadequate diet with respect to brain health (scores range from 0 to 14, with lower scores indicating a less adequate diet).14 breast cancer survivors will have recently completed adjuvant treatment (i.e., 6 months to three years previously), to ensure that perceived cognitive impairment is likely chronic and due to cancer. to achieve maximal effect, the study consists of two 12-week phases 1) intervention phase, 2) maintenance phase.


Eligibility criteria:
inclusion criteria: * previously diagnosed with stage i-iii breast cancer. * able to speak and read english. * able to consume foods orally. * \>18 years of age. * able to provide informed consent. * have no documented or observable psychiatric or neurological disorder that would interfere with study participation (e.g., schizophrenia). * report 'somewhat' to 'very much' cognitive impairment in the past week (i.e., a score ≥ 3 on a 1-5 scale) that they attribute to cancer or its treatment. * report a mind diet score \< 8 (range 0 to 14, higher score equates to higher diet quality). * willing to consume the mind diet. * completed adjuvant treatment 6 months to three years previously. exclusion criteria: * not meeting all of the inclusion criteria.
comparison of rice-richen and wheaten-richen meal on glucose control among chinese women with gestational diabetes melitus (gdm)

Conditions: Gestational Diabetes Mellitus in Pregnancy

Summary: since the prevalence of gestational diabetes melitus (gdm) increased by ..., as an important part of medical treatment, nutrition therapy is highly required to help patients achieve normoglycemia. carbohydrate intake is the primary nutrient affecting postprandial glucose levels,therefore the total amount and type of carbohydrate should be manipulated to blunt postprandial hyperglycemia. however,the type of carbohydrate has not yet been established. rice and wheaten food have similar glycemic index (gi),but some researches found the glucose response to them is different. a case-control study is designed to compare the glucose control status between rice-richen meal and wheaten-richen meal, and all other macronutrients and micronutrients are all calculated and same between two groups, which may provide more clues for type of carbohydrate recommendation for chinese women with gdm.


Eligibility criteria:
inclusion criteria: * pregnant women who undergo health examination in obstetric department in peking union medical college hospital. * 20-45 years old. * pregnant women who are diagnosed with gdm according to the american college of obstetricians and gynecologists (acog) diagnostic criteria during 24-28 weeks. * be ability to use mobile medical equipment, conditional follow-up of the mother and child. * voluntary participation in this study. exclusion criteria: * multiple pregnancy. * merger of serious diseases (such as hypertension, respiratory diseases, kidney disease, abnormal coagulation, immune system diseases, infectious diseases), history of adverse pregnancy (such as spontaneous abortion, habitual abortion), and history of gdm. * pregnant women with known diabetes before pregnancy, those requiring insulin or hormone therapy. * pregnant women who are deemed inappropriate to participate in this clinical study by her physician.
dexmedetomidine for prophylaxis against ponv in highly susceptible patients.

Conditions: Postoperative Nausea and Vomiting; Head and Neck Surgeries

Summary: the study aims to compare between two bolus doses of dexmedetomidine in preventing ponv in highly susceptible patients.

being a challenging complaint, many studies tried to find an effective preventive strategies for ponv. in this study protocol the investigators aim to compare between 0.5 mic/kg and 0.75 mic/kg bolus doses of dexmedetomidine when given toward the end of head and neck surgeries in highly susceptible patients with a controlled group receiving ondansetron. the primary outcome is the 1st 24 hours incidence of ponv other outcomes include: * time to 1st call for rescue antiemetic and the total amount of antiemetics * number of ponv attacks * post operative pain score with visual analogous scale (vas) and time to 1st call for rescue analgesia * sedation score using observer's assessment of alertness and sedation (oaa/s) * patient satisfaction * vital signs in the 1st 24 hours

Eligibility criteria:
inclusion criteria: * two risk factors or more for ponv ( female, non-smoking, postoperative opioids, history of motion sickness or ponv ) * head and neck surgeries in adults * asa ( i , ii ) exclusion criteria: * patients on ( steroids , antiemetics or any drug caude emesis ) * any active cardiac condition at the time of the surgery * pregnancy

Keywords: dexmedetomidine ponv ondansetron post operative nausea vomiting
a study of p38 inhibitor (4) monotherapy in patients with active rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this 4 arm study will compare the safety and efficacy, with regard to reduction of signs and symptoms, of p38 inhibitor (4) (50, 150 or 300mg po qd) monotherapy versus methotrexate monotherapy in adult patients with active rheumatoid arthritis. patients will be randomized to receive one of 3 doses of p38 inhibitor (4) or methotrexate. the anticipated time on study treatment is \<3 months, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients \>18 years of age, with active ra; * receiving treatment for ra on an outpatient basis; * females of child-bearing potential, or nonsterilized males with partners of child-bearing potential, must use reliable contraception during, and for 4 weeks after, the study. exclusion criteria: * major surgery within 8 weeks prior to screening; * rheumatic autoimmune disease or inflammatory joint disease other than ra; * treatment with methotrexate within 8 weeks of baseline; * concurrent use of dmards, including anti-tnf or other biologic therapy for ra.
cct-102 or expectant management in delayed pregnancy loss

Conditions: Early Pregnancy Loss, Delayed Pregnancy Loss

Summary: a phase 3, multi-center clinical trial of a cct-102 regimen or expectant management to promote uterine evacuation in first trimester non-progressing delayed pregnancy loss (dpl).

this is a phase 3, open-label, multi-center study to assess the efficacy of a cct-102 regimen for uterine evacuation in first trimester delayed pregnancy loss (dpl). eligible study participants will have ultrasound documented dpl with estimated gestational age 10 weeks or less. dpl is defined as arrest of embryonic or fetal development, in first trimester, where the cervix is closed and there is no or only slight bleeding. this includes: 1) anembryonic pregnancy, and 2) embryonic demise. expectant management, which is an accepted treatment protocol recognized in 2018 acog practice bulletin on early pregnancy loss (acog, 2018), consists of patient monitoring with no additional treatment. eligible participants will choose between the investigational product or expectant management on day 1. they will be evaluated for the primary endpoint (resolution of dpl) on study day 7. all participants will be followed to day 28.

Eligibility criteria:
inclusion criteria: 1. age 18 to 50 2. ability to provide informed consent 3. hemodynamically stable 4. closed cervical os 5. if fetus exists, clinical observation indicates gestation is no more than 10 weeks 6. diagnosis of delayed pregnancy loss, confirmed by ultrasound, based on: 1. embryonic demise: no embryonic cardiac activity when embryo measures 7 mm or greater; or, 2. anembryonic pregnancy: mean gestational sac diameter of 25 mm or greater, with no detectable embryo. exclusion criteria: 1. unwillingness or inability to comply with the study protocol and visit schedule 2. diagnosis of an incomplete or inevitable abortion including more than slight bleeding at enrollment and/or open os within the prior week. 3. confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass 4. hemoglobin \<10 g/dl 5. coagulation disorder, inherited porphyrias, and/or current anticoagulants use 6. chronic adrenal failure 7. concurrent chronic corticosteroid therapy 8. history of trophoblastic disease 9. current presence of an iud 10. history of allergy or contraindications to the use to mifepristone, misoprostol, or other prostaglandins 11. any condition that, in the opinion of the investigator, makes the patient unsuitable for study entry 12. any other current medical condition that jeopardizes the patient's ability to safely participate in the trial
a new speech, spatial, and qualities of hearing scale short-form for deaf children

Conditions: Deafness; Pediatric

Summary: deafness significantly affects several auditory tasks of everyday life in children: understanding speech in quiet and noisy environments, spatial location of sounds ... these difficulties in locating sound sources are often ignored by parents and underestimated by children. nowadays we there is specific tools to evaluate these problems in children. indeed, there is a validated french questionnaire (speech and spatial questionnaire ssq) for adults that evaluates auditory abilities, including sound localization, in different tasks of daily life. although robust, this questionnaire includes 49 questions and is too long for daily use in consultation. for this reason, moulin et al validated in 2018 a short version of the ssq questionnaire for adults with only 15 items. based on this model, the aim of this study is to develop and test a paediatric questionnaire with 12 items to assess more specifically auditory difficulties in deaf children. this questionnaire will follow the validated frame of the adult ssq questionnaire and will consist of three subscales: speech hearing (4 items), spatial hearing (4 items), and qualities of hearing (4 items). these 3 subscales are identical to those defined in long and short form pf the adult ssq questionnaire.


Eligibility criteria:
inclusion criteria: * male or female aged 7-17 (inclusive) * attending medical appointment for temporary or persistent deafness * able to understand the experimental instructions exclusion criteria: none-
ethnicity and analgesic practice in a pediatric emergency department

Conditions: Limb Fracture

Summary: early and appropriate pain management in the emergency department (ed) is an important aspect of child care. studies in the adult population revealed that ethnicity might be associated with disparities in analgesia and opioid treatment in ed patients suffering from limb fractures. the investigators aim to explore if ethnicity has an influence on analgesic practice in the pediatric ed. the objective of this study is to determine whether minority population arab children with orthopedic injuries are less likely than jewish children to receive oxycodone for limb fracture.

early and appropriate pain management in the emergency department (ed) is an important aspect of child care. studies in the adult population revealed that ethnicity might be associated with disparities in analgesia and opioid treatment in ed patients suffering from limb fractures. the investigators aim to explore if ethnicity has an influence on analgesic practice in the pediatric ed. the objective of this study is to determine whether minority population arab children with orthopedic injuries are less likely than jewish children to receive oxycodone for limb fracture .

Eligibility criteria:
inclusion criteria: -any patient with a limb fracture exclusion criteria: * multi trauma patients * patients with unidentified ethnicity

Keywords: patients who were admitted to the pediatric ed
effects of treating obstructive sleep apnea in epilepsy

Conditions: Epilepsy; Sleep Apnea; Obstructive Sleep Apnea

Summary: the purpose of this trial is to work out design issues prior to conducting a definitive phase 3 trial to determine whether treating sleep-related breathing disorders in people with epilepsy results in improvement in seizure control or an improvement in alertness during the day.

despite appropriate treatment with medications, individuals with epilepsy often continue to have seizures, and many suffer from excessive daytime sleepiness and poor quality of life. evidence from case studies suggests that treatment of coexisting obstructive sleep apnea (osa)-stoppage in breathing during sleep-can reduce the frequency of seizures in people with epilepsy that is resistant to antiepileptic medication. in this study, individuals with symptoms of osa and 2 or more seizures a month who meet study criteria will undergo polysomnography, a test that continuously monitors normal and abnormal physiological activity during sleep. those individuals who test positive for osa will be randomized to either therapeutic or placebo continuous positive airway pressure (cpap)-a mask treatment for sleep apnea-for 10 weeks, during which time seizure frequency, daytime sleepiness, health-related quality of life, and cpap compliance will be assessed.

Eligibility criteria:
inclusion criteria: * age of 18 years or older. * a history supportive of obstructive sleep apnea. * subject is able and willing to provide informed consent and to cooperate with polysomnography. * four or more quantifiable seizures per month. * subjects and their physicians agree to have their medication regimens optimized so that they are on the best regimen titrated to therapeutic benefit prior to the baseline phase of the study. exclusion criteria: * seizures secondary to drugs, alcohol, infection, neoplasia, demyelination, metabolic illness, or progressive degenerative disease. * non-epileptic spells (e.g., pseudoseizures) alone or in combination with epileptic seizures. * narcolepsy or another primary sleep disorder that requires intervention with medications and which may affect results of study (e.g., severe periodic limb movement disorder). * effectively treated osa or prior exposure to continuous positive airway pressure. * history of poor compliance with antiepileptic medications. * current treatment with the vagus nerve stimulator. * pregnancy. * a significant history of medical or psychiatric disease which may impair participation in the trial. * a history of alcohol or drug abuse during the one-year period prior to trial participation. * evidence of medical instability (e.g., congestive heart failure, cardiac arrhythmias, pulmonary disease) due to obstructive sleep apnea. * subjects who are unaware of the majority of their seizures and lack a reliable witness. * greater than ten seizures a day.

Keywords: epilepsy sleep apnea obstructive sleep apnea continuous positive airway pressure cpap
flare prevention study of canakinumab in patients with active systemic juvenile idiopathic arthritis (sjia)

Conditions: Systemic Juvenile Idiopathic Arthritis With Active Flare

Summary: this two-part study assessed the sustained efficacy of canakinumab in the double-blind part ii and the ability to taper steroids in the open label part i.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of systemic juvenile idiopathic arthritis as per international league against rheumatism (ilar) definition that must have occurred at least 2 months prior to enrollment with onset of disease \< 16 years of age. -arthritis in one or more joints with or preceded by fever of at least 2 weeks duration that is documented to be daily for at least 3 days with accompanying symptoms * active disease at the time of enrollment defined as follows: * at least 2 joints with active arthritis (using american college of rheumatology) acr definition of active joint) * documented spiking, intermittent fever (body temperature \> 38oc) for at least 1 day during the screening period within 1 week before first study drug dose * c-reactive protein \> 30 mg/l (normal range \< 10 mg/l) * no concomitant use of second line agents such as disease-modifying and/ or immunosuppressive drugs will be allowed with the exception of: * stable dose of methotrexate for at least 8 weeks prior to the screening visit, and/or folic/folinic acid per standard medical practice * stable dose of no more than one non-steroidal anti-inflammatory drug for at least 2 weeks prior to the screening visit * stable dose of steroid treatment \< or = to 1.0 mg/kg/day in 1-2 doses per day of oral prednisone or equivalent exclusion criteria: * diagnosis of active macrophage-activation syndrome (mas) within the last 6 months * risk factors for tuberculosis * patients with active or recurrent bacterial, fungal or viral infection at the time of enrollment, including patients with evidence of hiv infection, hepatitis b and hepatitis c infection other protocol inclusion/exclusion criteria may apply

Keywords: flare arthritis il-1beta antagonist systemic juvenile idiopathic arthritis juvenile rheumatoid
determination of predictive factors allowing to an additional 10% reduction of intra-ocular pressure

Conditions: Glaucoma, Primary Open Angle (POAG); Ocular Hypertension

Summary: to determine the predictive factors of a positive response to latanoprost 0.005% / timolol 0.5% fixed combination (defined as a 10% iop reduction from baseline), after 12 weeks of treatment (age, sex, ethnic origin, patient's medical history, family history of oag or oht, concomitant systemic treatment with beta-blockers, etiology, iop at baseline, corneal thickness, compliance, and adverse events).


Eligibility criteria:
inclusion criteria: * male or female patients, * aged \> than equal to 18 years, * patient presenting with an oht or oag with an iop � 21 mmhg, * patient currently treated with ophthalmic beta-blockers monotherapy and requiring a change of the ophthalmic medication due to insufficient response to treatment, exclusion criteria: * patient currently treated by or having received within the last month any ophthalmic hypotensive agent other than a beta-blocker, * patient presenting any contraindication to latanoprost or timolol, * patient with history of asthma, obstructive broncho-pneumopathy, sinusal bradycardia (pulse rate \< 60 bpm), auriculo-ventricular block, cardiac insufficiency, raynaud disease or any other condition that would preclude the patient from taking the prescribed medication, * patient with known intolerance to benzalkonium chloride or any excipient contained in the trial treatment,
evaluation of pesticide exposure in the general population

Conditions: Pesticide Poisoning

Summary: an association has been suggested with several diseases including cancer and iarc has classified several pesticides as carcinogenic, probably carcinogenic. there is a need for a better characterisation of environmental pesticides exposures and identification of suitable biomarkers of exposure and effect. a better understanding of the impact of pesticide exposure on metabolomic, transcriptomic and epigenetic changes, is essential to strengthen epidemiological hypotheses on the association with several cancer types. the main objective of the project is to validate a gis (geographic information system) based method to assess environmental pesticide exposures, using environmental (contamination of housedust) and biological (blood and urine samples) measures. the project aims further to investigate a potential link between housedust contamination and biological measures in healthy non-smoking male residents and explore the impact of environmental pesticide exposure on metabolomics, transcriptomic and epigenetic parameters.

the project involves a pilot phase involving repeated (twice) sampling in 20 male non-smoking volunteers living in the beaujolais region (france) to perform appropriate calibrations for metabolomic, transcriptomic and epigenetic analyses. the main study will be conducted in a sample of 150 male non-smoking volunteers and 50 professional pesticides applicators from the same region (3 sampling periods).

Eligibility criteria:
inclusion criteria: * non smokers in the last two years living in the beaujolais region (france) within 1000m of vignards informed consent signed exclusion criteria: * volunteers sharing the same households with professional applicators of pesticides